GFH009

DRUG2 trials

Sponsors

Genfleet Therapeutics (Shanghai) Inc.

Conditions

Large B-cell LymphomaRelapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Phase 1

A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

RecruitingNCT05934513

Genfleet Therapeutics (Shanghai) Inc.Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Start: 2023-09-06End: 2026-06-30Target: 95Updated: 2024-12-13

A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL

RecruitingNCT06375733

Genfleet Therapeutics (Shanghai) Inc.Large B-cell Lymphoma

Start: 2024-03-20End: 2026-12-31Target: 51Updated: 2025-08-12